Once-Weekly Insulin Showcases Promise in Phase III Diabetes Trials
Phase III Findings on Efsitora's Efficacy
Once-weekly insulin efsitora from Eli Lilly showed remarkable results in late-stage clinical trials for diabetes patients. In the QWINT-2 study, efsitora demonstrated a 1.34% reduction in A1C levels in insulin-naïve type 2 diabetes patients, compared to a 1.26% drop with daily insulin degludec. The non-inferior efficacy of efsitora positions it favorably in treatment plans.
Safety and Time in Range Observations
- Increased Time in Range: Patients on efsitora spent 45 minutes more in their target glucose range daily compared to those on degludec.
- Comparable Safety Profile: Efsitora's safety was similar to daily insulin, with an equal occurrence of severe hypoglycemic events.
Next Steps for Efsitora
Lilly is also positioning efsitora as a potential treatment option for type 1 diabetes patients. Continuing its advancement in the diabetes market, the company aims to outpace competitors.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.